The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Serum lipoprotein profile under different antihypertensive therapy.
Serum lipids of 80 patients with moderately severe essential hypertension under four different antihypertensive therapies were compared to ten matched hypertensives on a placebo  , after eight weeks of therapy . The results in the serum lipid parameters measured after therapy showed with enalapril a significant increase in high-density lipoprotein cholesterol ( HDL-C ) and a decrease in the total cholesterol/HDL-C ratio . With benazepril a significant decrease in the total cholesterol/HDL-C ratio was obtained . With the diuretic combination Epitens the effect on serum sodium and potassium was minimal . No significant changes were found in the lipoprotein profile following the administration of the placebo . Both angiotensin converting enzyme inhibitors ( enalapril and benazapril ) induced a significant improvement in the atherogenic ratio ; as well as the calcium antagonist ( isradipine ) , though to a less extent . The diuretic Epitens induced an insignificant deterioration of the atherogenic ratio
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .